Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati (Q30357011)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati |
scientific article |
Statements
1 reference
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati (English)
1 reference
Hagop M Kantarjian
1 reference
Michele Baccarani
1 reference
Jorge E Cortes
1 reference
Fabrizio Pane
1 reference
Marc Rudoltz
1 reference
Jerald P Radich
1 reference
Susan Branford
1 reference
Ricardo Pasquini
1 reference
Matt Kalaycio
1 reference
Beatriz Moiraghi
1 reference
Dong-Wook Kim
1 reference
Stuart L Goldberg
1 reference
Jacob M Rowe
1 reference
Elena Tothova
1 reference
Carmino De Souza
1 reference
Richard Yu
1 reference
Tillmann Krahnke
1 reference
Timothy P Hughes
1 reference
1 reference
Identifiers
1 reference